Samsung Biologics announced on July 20, 2026 that it has agreed to acquire PolyPeptide Group AG, the Swiss peptide CDMO, in an all-cash public tender offer. The price is CHF 44.31 per share, valuing PolyPeptide's equity at approximately CHF 1.46 billion (about USD 1.8 billion). It is the largest biopharmaceutical M&A transaction in South Korean history, and the clearest sign yet that peptide manufacturing capacity has become a strategic asset that large CDMOs prefer to buy rather than build.
Deal Terms at a Glance
- Offer: CHF 44.31 in cash per PolyPeptide share, for 100% of fully diluted share capital
- Equity value: approximately CHF 1.46 billion (~USD 1.8 billion)
- Premium: 40% over the undisturbed share price of CHF 31.65 (April 10, 2026, the last close before market rumors emerged); 11.6% over the 60-day volume-weighted average price
- Support: PolyPeptide's board unanimously recommends the offer; the largest shareholder, Draupnir Holding B.V. (~55.65% of outstanding shares), has committed to tender all of its shares
- Conditions: minimum acceptance of two-thirds of fully diluted shares plus regulatory approvals
- Timeline: formal offer prospectus expected by the end of August 2026; completion targeted for the end of 2026, after which PolyPeptide would be delisted from the SIX Swiss Exchange
Why Samsung Biologics Wants Peptide Capacity
Samsung Biologics built its position on monoclonal antibodies and ADCs. This deal extends it into peptides, one of the fastest-growing segments of the industry, driven by demand for GLP-1 therapies in obesity and diabetes. PolyPeptide brings more than 70 years of peptide API manufacturing history, over 1,000 therapeutic peptides produced, and a network of R&D and commercial manufacturing sites in Sweden, Belgium, France, the United States, and India.
The target's numbers explain the timing. PolyPeptide's preliminary first-half 2026 results, published alongside the offer, show revenue of EUR 236.6 million, up 41.6% year on year. Metabolic therapeutics now account for roughly 68% of total revenue, up from 56% a year earlier, and the Phase III development pipeline has grown to 37 projects. Its large-scale SPPS facility in Braine-l'Alleud, Belgium has been running at target utilization since the start of the year. In the current market, the binding constraint on peptide drug supply is manufacturing capacity, and this transaction buys that capacity directly.
What the Deal Means for Peptide Buyers
Consolidation at this scale changes the supplier landscape in two ways. First, the largest CDMOs are organizing themselves around commercial-scale GLP-1 programs, where multi-kilogram campaigns and long-term capacity agreements absorb most available reactor volume. Second, capacity that gets locked into strategic accounts becomes less accessible to early-stage and mid-size projects.
For research organizations and biotech companies, the practical consequence is a widening gap between commercial-scale manufacturing and the flexible, smaller-scale work that pipelines still depend on: feasibility batches, method development, impurity synthesis, and clinical trial material in the gram-to-hundred-gram range. Buyers increasingly run a two-track sourcing strategy—a large CDMO for the commercial process and a specialized partner for peptide CDMO development work and scale-up support—to keep early-stage timelines independent of big-ticket capacity negotiations.
Key Takeaways for the Industry
What did Samsung Biologics announce on July 20, 2026?
An all-cash tender offer to acquire 100% of PolyPeptide Group at CHF 44.31 per share, valuing the Swiss peptide CDMO at approximately CHF 1.46 billion. The board of PolyPeptide unanimously recommends the offer, and the largest shareholder has committed its ~55.65% stake. Completion is expected toward the end of 2026, subject to a two-thirds acceptance threshold and regulatory approvals.
Why are large CDMOs acquiring peptide manufacturers?
Demand for GLP-1 and other peptide therapeutics has grown faster than qualified manufacturing capacity. Building new GMP peptide capacity takes years of construction and validation, so established producers with running plants and regulatory track records command premium valuations. PolyPeptide's 41.6% half-year revenue growth, concentrated in metabolic programs, illustrates why.
Does this transaction change anything for research-scale peptide buyers?
Not immediately. The deal targets commercial API capacity, and its conditions run through the end of 2026. The longer-term effect to watch is capacity allocation: as large CDMOs prioritize strategic GLP-1 accounts, early-stage custom synthesis and development-scale work will continue to depend on specialized suppliers outside the consolidated platforms.
Sources
- Samsung Biologics: Samsung Biologics announces all-cash offer to acquire PolyPeptide (July 20, 2026). https://samsungbiologics.com/media/company-news/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide
- PolyPeptide Group: Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share — ad hoc announcement (July 20, 2026). https://www.polypeptide.com/news/samsung-biologics-announces-tender-offer-to-acquire-polypeptide-group-ag-for-chf-44-31-per-share/
- CHEManager: Samsung Biologics to Acquire PolyPeptide in All-Cash Deal, Expanding Global Manufacturing (July 20, 2026). https://chemanager-online.com/en/news/samsung-biologics-to-acquire-polypeptide-in-all-cash-deal-expanding-global-manufacturing
-
Synpeptide
peptide-focused CRO/CDMO company
The SynPeptide Research Team brings together scientists specializing in peptide synthesis, purification, and analytical characterization. Drawing on hands-on laboratory experience across custom and catalog peptides, the team shares evidence-based insights for researchers, formulators, and product developers. All content is reviewed against current scientific literature and internal quality-control data, reflecting SynPeptide's commitment to accuracy, reproducibility, and the responsible communication of peptide science.
